Galectin shares surge 12.28% intraday after positive Belapectin trial data and strong Q3 2025 financials.

Galectin Therapeutics Inc. (GALT) surged 12.28% intraday following the announcement of positive NAVIGATE trial results for Belapectin in treating cirrhotic portal hypertension caused by MASH, presented at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting. The company also reported strong financial results for the quarter ended September 30, 2025, reinforcing investor confidence. These developments, coupled with prior trial data showing reduced varices in U.S. patients, underscore progress in its MASH therapy pipeline. Additionally, a $10 million credit line secured earlier in the year provided further assurance of financial stability, supporting the stock’s upward momentum.